

Modulation of HIV-1 replication by RNA interference

Jean-Marc Jacque, Karine Triques & Mario Stevenson

Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, Massachusetts 01605, USA

RNA interference (RNAi) is the process by which double-stranded RNA (dsRNA) directs sequence-specific degradation of messenger RNA in animal and plant cells^{1,2}. In mammalian cells, RNAi can be triggered by 21-nucleotide duplexes of small interfering RNA (siRNA)³. Here we describe inhibition of early and late steps of HIV-1 replication in human cell lines and primary lymphocytes by siRNAs targeted to various regions of the HIV-1 genome. We demonstrate that synthetic siRNA duplexes or plasmid-derived siRNAs inhibit HIV-1 infection by specifically degrading genomic HIV-1 RNA, thereby preventing formation of viral complementary-DNA intermediates. These results demonstrate the utility of RNAi for modulating the HIV replication cycle and provide evidence that genomic HIV-1 RNA, as it exists within a nucleoprotein reverse-transcription complex, is amenable to siRNA-mediated degradation.

RNAi is a ubiquitous mechanism of gene regulation in plants and animals⁴ in which target mRNAs are degraded in a sequence-specific

manner⁵. RNAi is initiated by the dsRNA-specific endonuclease Dicer, which promotes processive cleavage of long dsRNA into double-stranded fragments between 21 and 25 nucleotides long, termed siRNAs⁵⁻⁸. Small interfering RNAs are incorporated into a protein complex that recognizes and cleaves target mRNAs⁹. Introduction of dsRNA into mammalian cells does not result in efficient Dicer-mediated generation of siRNA and therefore does not induce RNAi^{10,11}. The requirement for Dicer in maturation of siRNAs can be bypassed by introducing synthetic 21-nucleotide siRNA duplexes, which inhibits expression of transfected and endogenous genes in a variety of mammalian cells³. HIV-1 uses RNA intermediates in its replication. Therefore, we examined whether siRNA duplexes specific for HIV-1 were capable of effecting the degradation of viral RNAs necessary for completion of early and late events in the viral replication cycle.

We directed 21-nucleotide siRNA duplexes against several regions of the HIV-1 genome, including the viral long terminal repeat (LTR) and the accessory genes *vif* and *nef* (Fig. 1a). Small interfering RNA duplexes were co-transfected with an HIV-1 molecular clone (HIV_{NL-GFP}; ref. 12) into CD4-positive HeLa (Magi) cells¹³. Transfection of cells with an infectious molecular HIV-1 clone recapitulates late events in the viral life cycle, including production of viral RNAs, translation of viral proteins and release of virions. Compared with cells not transfected with siRNA duplexes, virus production, measured 24 h after transfection, was reduced 30-fold to 50-fold by homologous siRNAs (Fig. 1b). HIV production was inhibited to a lesser extent by single mismatch siRNAs (MTAR, M441), whereas a




Figure 1 Small interfering RNAs inhibit late events in HIV replication by promoting degradation of HIV-1 RNA. **a**, HIV targets of siRNAs used in this study. Small interfering RNAs completely homologous to the target HIV sequence (HIV_{NL-GFP}) are shown in blue and those harbouring nucleotide mismatches are shown in yellow. **b**, Effect of siRNAs on HIV-1 particle production. **c**, Total and active (phosphorylated) PKR levels in siRNA-transfected Magi cells. **d**, Small interfering RNAs mediate sequence-specific HIV RNA

degradation. The presence of HIV_{NL-GFP} or HIV_{YU-2} RNA was determined by RT-PCR using HIV Nef-specific primers. Because of the GFP insertion in HIV_{NL-GFP} Nef, RNAs originating from HIV_{NL-GFP} are 710 nucleotides larger than those originating from HIV_{YU-2}. **M**, molecular weight marker (100 bp ladder, New England Biolabs). **e**, Effect of siRNAs on HIV expression in primary PBLs.

letters to nature

vif siRNA with four mismatches (M98) did not inhibit HIV production (Fig. 1b). Activation of the dsRNA-activated protein kinase PKR leads to an inhibition of protein translation in a sequence-non-specific manner relative to the inducing dsRNA. Activation with PKR was not involved in the inhibition of the negative-strand RNA virus RSV (respiratory syncytial virus) by siRNAs¹⁴. Similarly, there was no significant induction of activated PKR (phosphorylated on Thr 446) over levels in non-transfected cells by any of the siRNAs (Fig. 1c). To further exclude a PKR effect, Magi cells were co-transfected with two HIV-1 variants (HIV-1_{NL-GFP}, HIV-1_{YU-2}; ref. 15) and with siRNAs that are specifically targeted to either virus. Because of the presence of a green fluorescent protein (GFP) insertion in Nef, HIV_{NL-GFP} should be targeted by the GFP-specific siRNA G388, whereas HIV_{YU-2}, which lacks a GFP insert, should be insensitive to G388. In addition, we exploited sequence differences in the *vif* genes of these viruses. The M98 siRNA contains four mismatches relative to the HIV_{NL-GFP} *vif* gene but is completely homologous to HIV_{YU-2} *vif*. Thus, M98 should direct the specific inhibition of HIV_{YU-2} RNA and not HIV_{NL-GFP} RNA. Because of the GFP insertion in HIV_{NL-GFP}, viral RNA produced in cells harbouring both viruses could be distinguished. In the absence of siRNAs, both HIV_{NL-GFP} and HIV_{YU-2} RNAs were evident in co-transfected cells (Fig. 1d). However, co-transfection with the G388 siRNA resulted in a loss of HIV_{NL-GFP} RNA but not HIV_{YU-2} RNA. Conversely, the M98 siRNA caused a loss in HIV_{YU-2} RNA without affecting HIV_{NL-GFP} RNA (Fig. 1d). This sequence-specific inhibition is inconsistent with a sequence-non-specific PKR effect and indicates that siRNAs are inhibiting HIV production by causing the specific degradation of viral RNA. We next examined

whether siRNAs could inhibit HIV gene expression (GFP fluorescence) in primary peripheral blood lymphocytes (PBLs), which are natural targets for HIV-1 infection. The frequency of GFP-expressing cells was markedly reduced in cells transfected with homologous siRNAs (T98, G388, *nef*) relative to cells transfected with mismatched siRNAs or non-transfected cells (Fig. 1e). The level of HIV_{NL-GFP} RNA, as determined by polymerase chain reaction with reverse transcription (RT-PCR), was also markedly reduced in cells transfected with homologous siRNAs (results not shown). Therefore, the components of siRNA-activated RNAi are fully functional in cells naturally targeted by HIV-1 infection.

Upon HIV-1 infection, genomic viral RNA is introduced into the host cell cytoplasm in the form of a nucleoprotein complex, which comprises viral proteins in association with genomic viral RNA¹⁶. Within this complex, the viral reverse transcriptase enzyme directs the synthesis of viral cDNA intermediates from the genomic viral RNA template. Recent studies with RSV have indicated that genomic viral RNA, which is tightly associated with nucleocapsid protein, is resistant to siRNAs¹⁷. We investigated whether siRNAs were able to direct the specific degradation of genomic viral RNA of HIV-1. The experimental design is outlined in Fig. 2a. Magi cells were transfected with the various siRNAs and infected with HIV_{NL-GFP} 20 h later. Transfection of cells with siRNAs did not significantly interfere with virus uptake *per se*, on the basis of levels of cell-associated p24 at 1 h after infection (Fig. 2b). The strategy for analysis of viral reverse-transcription intermediates in acutely infected cells is outlined in Fig. 2c. At 1 h after infection, genomic viral RNA was specifically detected in cells transfected with mismatched siRNAs and in non-transfected cells (M98, M441) but not




Figure 2 Small interfering RNAs block early events in HIV replication by promoting degradation of genomic HIV RNA. **a**, Experimental design. **b**, Levels of trypsin-resistant HIV gag p24 in siRNA-transfected cells. Dash indicates no siRNA transfected into the cells. **c**, Strategy for analysis of viral nucleic acid intermediates formed early after HIV infection. Major cDNA intermediates in viral reverse transcription are indicated. Blue line, viral RNA; red line, viral cDNA; open circles and squares, primer-binding sites for initiation of minus-strand synthesis and polypurine tracts for plus-strand synthesis, respectively. HIV-specific

primers (green arrows) are shown next to the earliest cDNA intermediate they amplify. Integrated (proviral) HIV DNA was amplified using an HIV LTR-specific primer (Rc) and a primer directed to *alcu* repeats (filled circles) within flanking cellular DNA. **d**, Effect of siRNAs on genomic viral RNA. **e**, Effect of siRNAs on formation of HIV-1 reverse transcription (RT) intermediates. **f**, Reduced levels of viral integration in siRNA-transfected cells.

in cells transfected with homologous siRNAs (Fig. 2d). Because genomic viral RNA is the template for the synthesis of viral cDNA intermediates, the synthesis of viral cDNAs, determined 36 h after infection, was dramatically inhibited in cells transfected with homologous siRNAs (T98, GFP, *nef*) (Fig. 2e). Small interfering RNAs bearing one-nucleotide mismatches (M441, M388) were partially inhibitory relative to the siRNA bearing four mismatches (Fig. 2e). Small interfering RNAs were quite stable in cells: HIV entry was suppressed to equal levels whether virus was added 20 h or 4 days after siRNA transfection (data not shown). Upon completion of viral cDNA synthesis, viral sequences integrate into cellular DNA to form a provirus. The level of provirus formation, as evidenced by the presence of junction sequences flanking viral and cellular DNA (Fig. 2e), was markedly reduced in cells transfected with homologous siRNAs (T98, G388, *nef*) relative to cells transfected with mismatched (M98) siRNAs or non-transfected cells (Fig. 2f). Collectively, these studies indicate that siRNAs interrupt early events in the HIV replication cycle by directing the specific degradation of genomic HIV-1 RNA, thereby preventing the subsequent synthesis of viral reverse-transcription intermediates and establishment of the provirus.

Expression of siRNAs from plasmid templates offers several advantages over synthetic siRNAs, such as stable selection under

selectable markers and inducible promoters, which are features that could be useful for genetic approaches to HIV therapy. Therefore, we examined whether expressed siRNAs could inhibit HIV. Modifying a strategy used previously in plants^{18,19}, we constructed plasmids containing a 19-base pair (bp) region of the HIV-1 *vif* gene in 5'-3' and 3'-5' orientations under the control of a T7 promoter (Fig. 3a). Virus production was determined 24 h after a three-way transfection of Magi cells with an HIV_{NL}-GFP molecular clone, the linearized *Vif* hairpin plasmid (TL *Vif*) and a vector expressing T7 RNA polymerase (T7 Pol). In the presence of T7 RNA polymerase, T7 transcripts derived from *Bst*BI-linearized expression plasmids would be predicted to comprise a GGUACC sequence from the T7 promoter, a 19-bp stem of self-complementary *Vif* sequences, a 3-, 5- or 7-nucleotide loop and a 3' UU overhang. All three *Vif* hairpin plasmids containing 3-, 5- or 7- nucleotide loops potentially suppressed virus production to 20–30-fold relative to non-transfected cells. By comparison, the presence of an identical plasmid lacking *Vif* sequences (TL Δ *Vif* or a control plasmid pcDNA) had no effect on virus production in co-transfected cells (Fig. 3b). This inhibitory effect on virus production was reflected by a loss of viral RNA (Fig. 3c). The *Vif* hairpin plasmid (TL *Vif*7) also inhibited viral gene expression in primary lymphocytes, whereas there was no inhibitory effect of the plasmid lacking *Vif* sequences in these cells (Fig. 3d). These results indicate that a sequence-specific RNAi effect can be activated in established and primary cells by siRNAs derived from self-complementary hairpin-generating plasmids. This provides a rationale for gene-therapy approaches to HIV that complement existing post-transcriptional approaches for inhibiting HIV, including ribozymes and antisense RNA (reviewed in ref. 20).

The involvement of RNAi in transposon silencing^{21,22} suggests that RNAi is an ancient antiviral system that may have evolved as a defence mechanism to protect the host from invasion by mobile genetic elements including transposons and viruses. Several studies have indicated that it is difficult to induce RNAi in mammalian cells using long dsRNAs. Although long dsRNAs can modestly inhibit gene expression in mammalian cells, the effects are not sequence specific^{3,23} and are more consistent with inhibition by the interferon response. Intriguingly, it is now becoming apparent that underlying the non-specific dsRNA-activated interferon response in mammalian cells, there may indeed be a sequence-specific RNAi effect that can be activated by long dsRNA^{24–26}. Silencing by long dsRNAs has now been observed in various cultured mammalian cells^{24,25}. The mechanism of silencing is consistent with RNAi because there is evidence that the long dsRNAs are processed to siRNAs and target RNAs are specifically degraded. Our results indicate that 21-nucleotide siRNAs promote HIV RNA degradation in primary lymphocytes, suggesting that the major target cell for HIV replication possesses functional components of the siRNA-induced silencing complex that mediates specific cleavage of target RNA². Future studies should determine whether sequence-specific RNAi that is independent of the interferon response can be activated against HIV by long dsRNAs. □

Methods

Synthesis of siRNA

The following RNA oligonucleotides were purchased from Dharmacon: T98 (5'-GGAAA GCUAAGGACUGGUUdTdT-3'); T283 (5'-AGCACACAGUAGACCCUGdTdT-3'); T441:5' -CUUGGCACUAGCAGCAUUAdTdT-3'); M98 (5' GAAAGCUAGGGGAUGGU UdTdT-3'); M441 (5' -CUUGGCACUACAGCAUUAdTdT-3'); G388 (5' -GACUUCAG GGAAGAUAGGCAdTdT-3'); M388 (5' -GACUUCAGGGGAGAUAGGCAdTdT-3'); *nef* (5' -GUGCCUGGCUAGAAGCAGdTdT-3'); TAR (5' -AGACCAGAUUCUGAGCCUG GdTdT-3'); and MTAR (5' -AGACCAGAUUAG CCUGGdTdT-3').

Plasmids

The T7 promoter was modified in the plasmid PCRscript (Stratagene) to form pCRT7. Oligonucleotides corresponding to nucleotides 5,323–5,342 of HIV-1 *vif* (Genbank accession number M19921) were inserted at the *Srf*I site of pCRT7. T7 Pol comprises T7 RNA polymerase from *Escherichia coli* BL21 (DE3) cloned into pcDNA 3.1 (Invitrogen).




Figure 3 Inhibition of HIV replication by siRNAs derived from plasmid DNA templates. **a**, Strategy for production of hairpin siRNAs from plasmid vectors. Linearization of each construct with *Bst*BI and transfection into cells with a plasmid expressing T7 RNA polymerase (Pol) predicts the expression of a hairpin RNA with a 19-bp self-complementary *Vif* stem and non-base-paired loops of 3, 5 and 7 nucleotides. **b**, Effect of *Vif* hairpin siRNAs on HIV particle production. TL Δ *Vif* is identical to plasmids that express *Vif* hairpin except that it lacks self-complementary *Vif* sequences. **c**, *Vif* hairpin siRNAs promote degradation of HIV RNA. PCR products amplified from HIV_{NL}-GFP served as a control. **d**, Inhibition of HIV-1 expression by *Vif* hairpin siRNAs in primary PBLs.

letters to nature

Cells and transfections

Magi cells were grown in DMEM containing 10% fetal bovine serum (FBS). PHA-activated PBLs were cultured in RPMI containing 10% FBS and 64 U ml^{-1} of interleukin-2 (ICN). Magi cells were transfected with oligofectamine (GIBCO) by the manufacturer's protocol in the presence of $1 \mu\text{g}$ HIV plasmid and/or 60 pmol of siRNA oligonucleotides. Transfection efficiencies were 75–85%. For PHA-activated PBLs, 5×10^6 cells were electroporated using a Gene Pulser apparatus (Bio-Rad) at 250 V , $960 \mu\text{F}$, resistance $R = \infty$ with $5 \mu\text{g}$ plasmid and/or 200 pmol siRNA. Transfection efficiencies were 30–50% of viable cells. Three-way transfections with siRNA expression plasmids comprised $0.1 \mu\text{g}$ T7 Pol, $0.5 \mu\text{g}$ pTL Vif and $0.5 \mu\text{g}$ pNLGFP (Magi cells), or $0.5 \mu\text{g}$ T7 Pol, $2 \mu\text{g}$ TL Vif and $2 \mu\text{g}$ pNLGFP (for primary lymphocytes). Transfected cells were centrifuged ($1,200\text{g}$) on DAKO silanized slides and examined under bright-field illumination or fluorescence (wavelength 516 nm) on a Zeiss Axioplan 2 microscope.

PCR analysis

Real-time PCR was performed as previously reported²⁷. Products were amplified from 5 to $20 \mu\text{l}$ of extrachromosomal DNA in $50\text{-}\mu\text{l}$ reactions containing $1 \times$ HotStart Taq buffer (Qiagen), 200 nM dNTPs, 400 nM primers and 1.5 U HotStart Taq. Two-LTR junctions were amplified by the primers Rc ($5'$ -TAGACCAGATCT GAGCCTGGGA- $3'$) and U5c ($5'$ -GTAGTTCTGCCAATCAGGG AAG- $3'$). Early products were amplified by the primers Ra ($5'$ -TCTCTGGTTAGACCAGATCTG- $3'$) and U5a ($5'$ -GTCTGAGGATCTCTAGTTAC- $3'$), and late products were amplified with U5b ($5'$ -GGGAGCTCTCTGGCTAACT- $3'$) and gag ($5'$ -GGATTAA CTGCGAATCGTTC- $3'$) primers. The oligonucleotide probe for real-time PCR was as previously reported²⁷.

Viral assays

For RT-PCR, $1\text{--}2 \mu\text{g}$ RNA was reverse transcribed and amplified by PCR using the Nef primers Na ($5'$ -GACAGGGCTTGGAAAGG- $3'$) and Nb ($5'$ -TTAGCAGTTCTGAA GTACTC- $3'$) as described previously²⁸. The integration assay was performed on DNazol-extracted total DNA (Invitrogen) using the Alu primer SB704 ($5'$ -TGCTGGGATTACAG GCGTGAG- $3'$) and primer Rc for the first round of PCR (25 cycles). Nested PCR was performed under the same conditions using primers M667 ($5'$ -GGCTAACTAGGGAA CCCACTG- $3'$) and AA55 ($5'$ -CTGCTAGAGATTTCACACTGAC- $3'$). For virus production, viral p24 (capsid) was measured by enzyme-linked immunosorbent assay according to the manufacturer's protocol (Beckman-Coulter). Reverse transcription activity was measured as previously reported²⁸.

PKR assay

We electrophoresed $20 \mu\text{g}$ of whole-cell lysates in triple detergent lysis buffer on a 10% SDS-polyacrylamide gel and electrotransferred to a nitrocellulose membrane (Amersham Hybond C+). The membrane was probed with a phospho-Thr 446 PKR-specific antibody or a PKR-specific antibody (Upstate Biotechnology).

Received 25 March; accepted 7 June 2002; doi:10.1038/nature00896.
Published online 26 June 2002.

- Sharp, P. A. RNA interference—2001. *Genes Dev.* **15**, 485–490 (2001).
- Hutvagner, G. & Zamore, P. D. RNAi: nature abhors a double-strand. *Curr. Opin. Genet. Dev.* **12**, 225–232 (2002).
- Elbashir, S. M. *et al.* Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**, 494–498 (2001).
- Fire, A. *et al.* Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806–811 (1998).
- Zamore, P. D., Tuschl, T., Sharp, P. A. & Bartel, D. P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. *Cell* **101**, 25–33 (2000).
- Elbashir, S. M., Lendeckel, W. & Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. *Genes Dev.* **15**, 188–200 (2001).
- Hammond, S. M., Bernstein, E., Beach, D. & Hannon, G. J. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* **404**, 293–296 (2000).
- Bernstein, E., Caudy, A. A., Hammond, S. M. & Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature* **409**, 363–366 (2001).
- Nykanen, A., Haley, B. & Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. *Cell* **107**, 309–321 (2001).
- Caplen, N. J., Fleenor, J., Fire, A. & Morgan, R. A. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. *Gene* **252**, 95–105 (2000).
- Uti-Tei, K., Zennu, S., Miyata, Y. & Saigo, K. Sensitive assay of RNA interference in *Drosophila* and Chinese hamster cultured cells using firefly luciferase gene as target. *FEBS Lett.* **479**, 79–82 (2000).
- Welker, R., Harris, M., Cardel, B. & Krausslich, H. G. Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. *J. Virol.* **72**, 8833–8840 (1998).
- Kimpton, J. & Emerman, M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β -galactosidase gene. *J. Virol.* **66**, 2232–2239 (1992).
- Bitko, V. & Barik, S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. *BMC Microbiol.* **1**, 34–45 (2001).
- Li, Y. *et al.* Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replication-competent and -defective viral genomes. *J. Virol.* **65**, 3973–3985 (1991).
- Moore, J. & Stevenson, M. New targets for inhibitors of HIV-1 replication. *Nature Rev. Mol. Cell Biol.* **1**, 40–49 (2000).
- Bitko, V. & Barik, S. An endoplasmic reticulum-specific stress-activated caspase (caspase-12) is

- implicated in the apoptosis of A549 epithelial cells by respiratory syncytial virus. *J. Cell Biochem.* **80**, 441–454 (2001).
- Wang, M. B. & Waterhouse, P. M. High-efficiency silencing of a β -glucuronidase gene in rice is correlated with repetitive transgene structure but is independent of DNA methylation. *Plant Mol. Biol.* **43**, 67–82 (2000).
- Varshawesley, S. *et al.* Construct design for efficient, effective and high-throughput gene silencing in plants. *Plant J.* **27**, 581–590 (2001).
- Dornburg, R. & Pomerantz, R. J. HIV-1 gene therapy: promise for the future. *Adv. Pharmacol.* **49**, 229–261 (2000).
- Ketting, R. F., Haverkamp, T. H., van Luenen, H. G. & Plasterk, R. H. Mut-7 of *C. elegans*, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD. *Cell* **99**, 133–141 (1999).
- Tabara, H., Hill, R. J., Mello, C. C., Priess, J. R. & Kohara, Y. *pos-1* encodes a cytoplasmic zinc-finger protein essential for germline specification in *C. elegans*. *Development* **126**, 1–11 (1999).
- Caplen, N. J., Parrish, S., Imani, F., Fire, A. & Morgan, R. A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. *Proc. Natl Acad. Sci. USA* **98**, 9742–9747 (2001).
- Billy, E., Brondani, V., Zhang, H., Muller, U. & Filipowicz, W. Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. *Proc. Natl Acad. Sci. USA* **98**, 14428–14433 (2001).
- Paddison, P. J., Caudy, A. A. & Hannon, G. J. Stable suppression of gene expression by RNAi in mammalian cells. *Proc. Natl Acad. Sci. USA* **99**, 1443–1448 (2002).
- Yang, S., Tutton, S., Pierce, E. & Yoon, K. Specific double-stranded RNA interference in undifferentiated mouse embryonic stem cells. *Mol. Cell Biol.* **21**, 7807–7816 (2001).
- Sharkey, M. *et al.* Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. *Nature Med.* **6**, 76–81 (2000).
- Brichacek, B. & Stevenson, M. Quantitative competitive RNA PCR for quantitation of virion associated HIV-1 RNA. *Methods* **12**, 294–299 (1997).

Acknowledgements

We thank A. Mann for research support, C. Mello and P. Zamore for discussions, B. Mellor for preparation of the figures, and T. Pinkos for manuscript preparation. We also acknowledge assay support provided by the University of Massachusetts Center for AIDS Research. HIV_{YU-2} was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), from B. Hahn and G. Shaw. This study was supported by grants from the NIH and the Jenner Foundation to M.S.

Competing interests statement

The authors declare that they have no competing financial interests.

Correspondence and requests for materials should be addressed to M.S.
(e-mail: mario.stevenson@umassmed.edu).

E3 ubiquitin ligase that recognizes sugar chains

Yukiko Yoshida^{*}, Tomoki Chiba^{†‡}, Fuminori Tokunaga[§], Hiroshi Kawasaki^{||}, Kazuhiro Iwai[§], Toshiaki Suzuki^{†‡}, Yukishige Ito^{||}, Koji Matsuoka[#], Minoru Yoshida^{†☆}, Kelji Tanaka^{†‡} & Tadashi Tai^{*}

^{*} Departments of Tumor Immunology and [†] Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, Bunkyo-ku, Tokyo 113-8613, Japan
[‡] CREST, Japan Science and Technology Corporation (JST), Saitama 332-0012, Japan,

[§] Department of Molecular Cell Biology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan

^{||} Kihara Institute for Biological Research, Graduate School of Integrated Science, Yokohama City University, Yokohama, Kanagawa 244-0813, Japan

[¶] Synthetic Cellular Chemistry Laboratory, and [☆] Chemical Genetics Laboratory, RIKEN, Wako, Saitama 351-0198, Japan

[#] Department of Functional Materials Science, Saitama University, Saitama, 338-8570, Japan

N-glycosylation of proteins in the endoplasmic reticulum (ER) has a central role in protein quality control^{1–3}. Here we report that N-glycan serves as a signal for degradation by the Skp1-Cullin1-Fbx2-Roc1 (SCF^{Fbx2}) ubiquitin ligase complex. The F-box protein Fbx2 (ref. 4) binds specifically to proteins attached to